Drug Type Monoclonal antibody |
Synonyms LM 102, LM102 |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 06 Oct 2021 | |
CLDN18.2 positive Solid Tumors | Phase 2 | CN | 06 Oct 2021 | |
Bile Duct Neoplasms | IND Approval | CN | 27 Oct 2022 | |
Pancreatic Cancer | IND Approval | CN | 27 Oct 2022 | |
Stomach Cancer | IND Approval | CN | 27 Oct 2022 | |
Solid tumor | IND Approval | CN | 12 Jun 2021 |